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Abstract
Preventive chemotherapy campaigns with praziquantel and albendazole are being imple-
mented in Angola, as a high priority public health intervention. However, there are no pub-
lished data regarding adverse events associated with these medications. In this context, we
analysed adverse events due to co-administration of praziquantel and albendazole in endemic
areas of schistosomiasis and soil-transmitted helminths in Bengo, Angola. In the context of a
targeted drug administration, between December 2012 and September 2013, we conducted
two surveys after co-administrating single oral doses of praziquantel and albendazole tablets
to children 2 to 15 years of age. About 24 hours after each treatment, participants answered a
questionnaire about adverse events. At baseline, 605 children (55.0% male; mean age: 9.7
years) were treated; 460 were interviewed and 257 (55.9%) reported at least one adverse
event, 62.3% (160/257) of children being infected with schistosoma haematobium. After six
months of treatment, among 339 children surveyed, 184 (54.3%) reported adverse events,
with 49.5% (91/184) of infected children. Adverse events were most common in preschool-
aged children, with no significant difference between genders. The most frequent adverse
events in the two surveys were abdominal pain (18.5%, 25.7%), headache (20.9%, 23.0%)
and dizziness (15.7%, 19.8%). Children aged 12 to 15 years (adjusted OR = 0.40, p = 0.040)
and those with mixed infection (adjusted OR = 0.04, p = 0.011) had lower odds of adverse
events. After the second treatment, those with heavy infection (adjusted OR = 2.72, p =
0.018) and aged 9–11 years (adjusted OR = 2.01, p = 0.049) had significantly fewer adverse
events. About 2.0% of children experienced severe adverse events. This study adds evidence
that preventive chemotherapy for schistosomiasis and soil-transmitted helminths control is
safe, but cases of adverse events are expected. Standardized methodologies to discriminate
drug-related adverse events from the clinical manifestations of the infections are needed.
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Introduction
Neglected tropical diseases (NTD), including schistosomiasis and soil-transmitted helminths
(STHs), remain important public health issues in developing countries, where lack of adequate
clean water and poor sanitation are common [1–3]. Schistosomiasis is one of the most socio-
economically devastating parasitic disease in the world, causing estimated 280 thousand deaths
and 4.5 million Disability Adjusted Life Years (DALYs) [4]. On the other hand, STHs, namely
infections by Ascaris lumbricoides, Trichuris trichiura and hookworms, affect more than one
billion individuals worldwide, causing respectively, 60, 10 and 65 thousand deaths, respectively
[5,6]. In Angola, the prevalence of those diseases are high and variable within the country [7].
Recently, in a community based survey conducted by Figueiredo et al [8] in the Dande munici-
pality (northern Angola), prevalence of urogenital schistosomiasis in preschool-aged children
(PSAC) and school-aged children (SAC) were reported to be 10% and 17%, respectively, with
10% of anaemia cases in the studied population. The same study determined the prevalence of
infection by at least one STH of 22.6% in preschool-aged children and 31.6% in school-aged
children in the Dande municipality [8]. Another study conducted in the same region found an
association between A. lumbricoides infection and malnutrition in children [9].
Preventive chemotherapy (PC) refers to the periodic administration of anthelminthic drugs
to populations at risk of morbidity, with the aim to reduce infection intensity and eliminate
moderate and heavy infections [10]. Thus, mass drug administration (MDA) is the corner-
stone of the current global strategy to control helminthiasis. In children aged 2 to 15 years,
Schistosomiasis is recommended to be controlled by taking a single dose (40mg/Kg child
weight) of praziquantel (PZQ) and STHs with a single dose (400mg) of albendazole (ALB)
[11]. ALB has a remarkable safety record, considering that a very low frequency and incidence
of adverse events (AEs), mainly gastrointestinal, are described in the literature [12,13]. On the
other side, despite that minimal and transient adverse events are described to occur with PZQ
(reported mainly in heavily infected people and normally associated to the response of the host
immune system to the dying worms), serious adverse reactions can also take place and may
reduce drug compliance [13–21]. In fact, AEs resulting from co-administrating both drugs are
described to be similar in severity to those experienced with monotherapy, however, informa-
tion regarding the safety of this combination in children under 4 years of age (or under 94 cm
in height) is scarce, especially in Angola [22]. As a consequence, preschool-aged children
(PSAC) were considered ineligible for MDA with PZQ and the control approach were the
referral to health facilities for individual case management [11].
According to WHO guidelines [10,11], AEs occur 24–48 hours after drug administration
but do not necessarily have a causal relationship with treatment. They may be mild when not
affecting daily activities (e.g. playing) or moderate when affecting the performance of daily
activities. However, severe AEs require complete rest and / or medication, while serious AEs
are life-threatening and require admission to the hospital.
In 2010 WHO recognized that preschool-aged children were a high-risk group for schisto-
somiasis (when living in highly endemic settings), that should also be included in public health
interventions, along with school-aged children and woman in childbearing age [15,23]. This
was followed by several reports on the safety of PZQ in preschool-aged children (between 1
month and 7 years) and the recognition that administrating PZQ to those children was safe
and efficacious [11,18,23–25]. Nevertheless, Angola is an endemic country for schistosomiasis
and STHs and the therapeutic policy for those diseases is presently aligned with the 2006
WHO guidelines [11]. Currently, and at a national level, diagnosed cases of schistosomiasis in
school-aged children are recommended to be medically treated at health care units and control
activities for STHs are based in deworming campaigns [7,11].
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Therefore, further evidence on adverse events (AEs) to the co-administration of PZQ and
ALB, experienced in the context of TDA campaigns, are needed. Additionally, there is no pub-
lished data in Angola regarding adverse events associated to the co-administration of PZQ and
ALB, either in preschool-aged (particularly in under 4) or school-aged children. Thus, consid-
ering that the local health authorities of the NTD control program are implementing regular
helminth control campaigns, these data are essential to inform these programs and to fill the
treatment gap for children under 4 (currently excluded from TDA and often neglected).
Consequently, this pioneering study was carried out in the community of Cabungo and the
Porto Quipiri School, located in the study area of the CISA project (Angola Health Research
Centre, translated). We aimed to analyse the adverse events experienced following co-adminis-
tration of PZQ and ALB for preventive chemotherapy against schistosomiasis and STHs.
Methods
Study site
We conducted this study between December 2012 and September 2013, in Cabungo commu-
nity and Porto Quipiri School, located in the study area of CISA, in the Dande Municipality,
Bengo Province—northern Angola. These hamlets were selected due to high prevalence of
SCH, STHs and malaria observed in the area, whose structure, dynamics and geographical dis-
tribution of the population was previously described by Costa et al (2012) [26] and the epide-
miology of schistosomiasis and STHs was detailed recently by Sousa-Figueiredo et al (2012)
[8].
Study design and aim
This is a longitudinal study, conducted in the context of a plan intervention by local health
authorities, aiming to investigate the adverse events experienced by PSAC and SAC following
the mass drug co-administration of PZQ and ALB, for the control of schistosomiasis and
STHs at baseline and 6 months after the first treatment.
Participants and therapeutic intervention
For this study, we enrolled 605 children, of whom 460 (76.0%) and 339 (56.0%) successfully
participated in the first and second survey for AEs, respectively. All children, aged between 2
to 15 years old and living in those areas, were invited to participate and received a kit contain-
ing single doses of PZQ (40mg/kg), using the dose pole method to determinate the number of
PZQ tablets to be administered to each child, and single doses of ALB (400mg) tablets. The
tablets were crushed or broken when necessary and given with water or juice, as recommended
by others [26], taken under direct observation of a health professional onsite. We also timely
treated, with artemeter-lumefantrine (AL-20/120mg), children tested positive for malaria as
recommended by the National Malaria Control Program [27]. In addition, refusals or failure
in successful administration was documented. We excluded children if any severe adverse
events were reported to be experienced in previous administration of PZQ and ALB.
Laboratory analysis
Pre-treatment stool samples were collected for the diagnosis of intestinal parasites (Schisto-
soma mansoni, hookworms, Ascaris lumbricoides, Trichuris trichuria and Hymenolepis nana),
performed by Kato-Katz method [28,29], and the presence and intensity of S. haematobium
was determined by the examination of the pellet resulting from 10ml centrifuged pre-treat-
ment urine [28]. The intensity of S. haematobium infection was recorded as light, moderate
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and heavy if 1–49, 50–499 and equal or more than 500 eggs per 10 ml of urine were observed,
respectively, according to WHO recommendations [30]. We collected capillary blood samples
for the diagnosis of uncomplicated malaria, performed by rapid diagnostic tests (RDTs)
according to the manufacturer (SD BIOLINE Malaria Ag P.f/P.v, Standard Diagnostics, Inc).
For the measurement of haemoglobin levels, we used the Hemocue System (HemoCue1 201
+, Angelholm, Sweden).
Adverse events data collection
We used a structured questionnaire to collect information on the adverse events (AEs) experi-
enced by the children, performed to caretakers between 24 and 72 hours after treatment.
When the caretaker was, absent and children had discernment to respond, the interview was
performed with the children. Mild-to-moderate AEs were defined as undesirable experiences
following drug administration, similarly to others, and severe AEs were defined as symptoms
and signs due to administration drugs, which forced parents or caretaker to take their children
to the health facility to be observed or hospitalized [31].
Statistical analysis
The collected data was first entered into the CISA database and then statistical analysis was
conducted with SPSS version 23.0 computer software (IBM Corporation, New York, USA).
Pearson’s chi-square tests were used to compare the occurrence of AEs between the two sur-
veys and for categorical variables. Alternatively, Fisher’s exact test was used when any 2x2 con-
tingency table cell expected a count below five.
We performed binary logistic model to identify possible independent predictors of AEs in
the two surveys, using adjusted odds ratios (OR) and their 95% confidence interval (CI). The
threshold for significant level was 0.05.
Ethics
All procedures performed in this study were in accordance with the standards of the 1964 Dec-
laration of Helsinki and its later amendments. The Ethics Committee of the Angolan Ministry
of Health approved the study protocol and all use of secondary data. Written informed consent
was obtained and signed by a guardian, parent or a caretaker for each of the participants. A
copy of the signed consent form, as well as contact information, was subsequently delivered to
each participant. The Provincial health office, local leaders and parents were previously
informed about the study in the area.
Results
A total of 605 children aged between 2 to 15 years (55.0% of males, 333/605) mean age 9.7
years ± 3.5, were subject to preventive chemotherapy with PZQ and ALB. Children with RDT
positive for malaria were also treated with AL. At the baseline, of the 605 participating chil-
dren, 548 took PZQ + ALB tablets while 57 took PZQ + ALB + AL. From those, 460 interviews
were performed (76.0%, 460/605), responded mainly by the children themselves (75.0%) and
guardians (25.0%). AEs were reported by 257 (55.9%, 257/460) children, 22 PSAC and 235
SAC. In this group of participants, 62.3% (160/257) were infected with either S. haematobium
(100.0%, 160/160), STHs (20.6%, 33/160) and/or Plasmodium falciparum (19.4%, 31/160). On
the other hand, 64.0% (130/203) of children, that had not experienced AEs, were also infected
with those parasites (Fig 1). At the sixth month follow-up, 339 children included at the base-
line, were surveyed for AEs after second round of medications (with PZQ+ALB or with PZQ
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+ALB+AL), from which 184 (54.3%, 184/339) reported to have experienced at least one
adverse event, 19.6% (36/184) PSAC and 80.4% (148/184) SAC, as shown in Fig 1.
No significant difference in the characteristics between participants and dropout children
were observed at baseline. However, after the second round of treatment, a significantly lower
proportion of PSAC (98.1% to 1.9%, p<0.001) and SAC (75.9% to 24.1%, p<0.001) were
observed in the dropout group (Table 1).
In the first survey, headache (20.9%, 96/460), abdominal pain (18.5%, 85/460) and dizziness
(15.7%, 72/460) were the three most frequently reported AEs. PSAC experienced mainly head-
ache (18.6%), vomiting (14.3%) and abdominal pain (7.1%), whereas SAC, after headache
(21.3%) and abdominal pain (20.5%) reported dizziness (18.2%). PSAC experienced signifi-
cantly more vomiting than SAC (14.3% vs 6.7%, p = 0.029). SAC in turn experienced more
abdominal pain (20.5% vs 7.1%, p = 0.008) and dizziness (18.2% vs 1.4%, p<0.001). Blood in
stool and light sensitivity was only reported for SAC. After the second treatment, reports of
abdominal pain, headache, dizziness and fatigue were also more frequent.
In this survey, PSAC reported significantly more fatigue (30.2% vs 15.4%, p = 0.009), blood
in urine (20.8% vs 5.6%, p<0.001) and blood in stool (7.5% vs 1.0%, p = 0.002). Light sensitivity
was not experienced by PSAC in both treatments, neither breathing difficulty after the second
treatment (see Table 2).
Although, 2.3% (6/257) of children reporting AEs after the first treatment, and 1.6% (3/184)
after the second treatment searched for medical attention in a nearby health facility but no
admission notification was reported. Data on hospital care was not collected and therefore
classification of the seriousness of AEs was not possible to perform.
Most children reported two simultaneous AEs followed by those reporting only one event
(32.1% vs 31.5% in the first survey and 30.7% vs 29.2% in the second survey). There were also
children who reported three or more simultaneous events. The most common single AEs were
abdominal pain (37.9%, 22/58), headache (29.3%, 17/58) and fatigue (17.2%, 10/58) while dou-
ble AEs were “abdominal pain + headache” (15.3%, 9/59), “fatigue + dizziness” (11.9%, 7/59)
and “abdominal pain + fatigue” (6.8%, 4/59). Triple AEs were “abdominal pain + headache
+ dizziness” (12.1%, 4/33) and “abdominal pain + fatigue + dizziness” (6.1%, 2/33).
In the first survey, we observed that children with mixed infections had lower odds ratio to
develop AEs than those with simple infections (adjusted OR = 0.14, p = 0.016 vs adjusted
OR = 0.04, p = 0.011). Only the age group from 12 to 15 years old presented a significant OR
of developing AEs (adjusted OR = 0.40, p = 0.040). All of these associations observed in the
first survey lost their statistical significance after the second treatment. However, children with
severe S. haematobium infection (adjusted OR = 2.72, p = 0.018) and children aged 9 to 11
years (adjusted OR = 2.01, p = 0.049) were significantly more probability to have AEs.
(Table 3).
Discussion
In this study, 55.9% of the children who completed both surveys reported having experienced
AEs after the first treatment with ALB, PZQ and/or AL and 54.3% after the second treatment.
In general, the main AEs reported were abdominal pain, headache and dizziness, both after
the first and after the second treatment, and only a low proportion of children searched for
medical attention after both treatments (2.3% and 1.6%, respectively). The present study
reported different proportions of AEs comparable to those found in other studies involving
praziquantel and / or albendazole. However, there are variations that may occur due to the het-
erogeneous antecedents of the participating individuals, such as age, nutritional and immuno-
logical status, socioeconomic conditions, environmental exposure, prevalence and intensity of
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infection, stage of parasite development, etc[13,18,20,21,31–37]. Zwang et al reviewed the effi-
cacy and safety of PZQ (40mg/kg), and report that the main AEs experienced and their inci-
dences are mainly abdominal pain (31.8%), muscle pain (29.2%), joint pain (20.2%), headache
(13.6%), diarrhoea (12.9%), fatigue (9.6%), nausea (10.6%), dizziness (11.9%), vomiting (7.9%)
and itching (9.8%) [18]. Additionally for ALB, there are reports of the occurrence of epigastric
pain, dry mouth, fever and itching [18,21,32,38–40]. However, the occurrence of AEs are
reported to be associated with the proportion of dying S. haematobium worms, i.e., with the
pharmacologic effect of the drug on the parasite (for example; abdominal pain is reported to
be associated with the deposition of dead worms in the mesenteric veins), they can also occur
due to the natural course of disease [19,32,37,41,42].
Neumayr et al mentions that symptomatic acute schistosomiasis or treatment-induced
reactions can manifest themselves with identical symptoms [32]. This group and others further
discuss that the exposure to a high level of parasite antigens, caused by larval migration and
maturation (of helminth larvae) or early oviposition in symptomatic acute schistosomiasis,
can lead to an immune overreaction, resulting in symptoms that are similar to those reported
as AEs to PZQ, but totally independent from treatment [19,32,43–45]. Although increasing the
number of infections significantly reduced the chances of AE occurrence, we found that heavy
S. haematobium infection was significantly associated with AEs occurrence, with odds ratio
twice as high in individuals with this parasitic load in the second survey.Also, H. nana infec-
tions alone can cause headache, dizziness, abdominal pain and diarrhoea, A. lumbricoides can
cause nausea, vomiting, diarrhoea and abdominal pain, T. trichiura can cause abdominal pain
and diarrhoea, and S. stercoralis can cause erythema, itching, fever, abdominal pain and
Fig 1. Study participants and dropouts. PSAC, preschool-aged children; SAC, school-aged children; SCH, schistosomiasis; SHTs,
soil-transmitted helminths; AEs, adverse events; PZQ, praziquantel; ALB, albendazole; AL, Artemeter-Lumefantrine.
https://doi.org/10.1371/journal.pone.0229247.g001
Table 1. Characteristics of participants and dropouts in AEs survey.
Baseline (n = 605) 6 months follow-up (n = 431)
Characteristics Participants n = 460
(76.0%)
Excluded n = 145
(24.0%)
P value� Participants n = 339
(78.7%)
Excluded n = 92
(21.3%)
P value�
Age group
PSACa 70 (77.8) 20 (22.2) 0.674 53 (98.1) 1 (1.9) <0.001
SACb 390 (75.7) 125 (24.3) 286 (75.9) 91 (24.1)
Gender
Male 258 (77.5) 75 (22.5) 0.357 193 (80.1) 48 (19.9) 0.415
Female 202 (74.3) 70 (25.7) 146 (76.8) 44 (23.2)
S. haematobium eggs
Positive 290 (76.1) 91 (23.9) 0.951 159 (81.5) 36 (18.5) 0.184
Negative 170 (75.9) 54 (24.1) 180 (76.3) 56 (23.7)
Soil-transmitted helminths
eggs
Positive 156 (80.4) 38 (19.6) 0.058 58 (90.6) 6 (9.4) 0.603
Negative 205 (71.7) 81 (28.3) 163 (87.2) 24 (12.8)
Missed examination 99 (79.2) 26 (20.8) 118 (65.6) 62 (34.4)
� chi-square test
a Preschool-aged children
b School-aged children.
https://doi.org/10.1371/journal.pone.0229247.t001
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diarrhoea [35,38,46]. Thus, we postulate that children with mixed infections between schisto-
somiasis, STH and hymenolepiasis can be manifesting additive drug-unrelated AEs, overesti-
mating the frequency of AEs reported here.
Despite that other authors have found no progression of AEs between treatment rounds,
we found that after the second treatment the reports of abdominal pain, headache, dizziness
and fatigue generally increased and the reports of joint pain and breathing difficulty generally
decreased [20]. Additionally to that, experiencing 2 simultaneous AEs was slightly more fre-
quent than experiencing only one event, and experiencing 3, 4 or 5 simultaneous events was
also reported, despite of less frequent. Considering that the literature reports an association
between AEs and the intensity of infection and anemia status, we found a statistically signifi-
cant association between heavy infection and AEs [18,20,36]. Nevertheless, it should be consid-
ered that the administration of PZQ following a high-lipid or high-carbohydrate diets can
increase its bioavailability (by a factor of 2.7 and 3.9) and in turn may alter the pharmacoki-
netic profile of the drug, possibly influencing the effect of the drug on the parasite and proba-
bly the frequency and type of AEs [18,19,33,41]. In this study children aged 9 to 15 years old,
were at lower risk of experiencing AEs than younger children, however, it should be consid-
ered that this association lost their statistical significance after the second treatment and that
the number of individuals within the PSAC group is small. Thus, these results should be inter-
preted carefully. Nevertheless, similar frequencies of AEs were observed by others between
preschool and school children [21].
Regarding the 45% of “uninfected” children experiencing AEs in our study, in addition to
the fact that these children may have AEs due to drug use only; we also considered the stages
of infection undetected by the diagnostic technique used here [43,47]. The limited effect of
PZQ on young forms of parasites and the progression of disease would still manifest signs and
symptoms [40,43,47].
Table 2. Frequency of reported AEs of children treated with PZQ and ALB in two medication rounds.
Adverse events 1st survey 2nd survey
PSACa 70 (15%) SACb 390 (85%) Total 460 (100%) p value� PSACa 53 (16%) SACb 286 (84%) Total 339 (100%) P value�
Overall 22 (31.4) 235 (60.3) 257 (55.9) <0.001 36 (67.9) 148 (51.7) 184 (54.3) 0.043
Abdominal pain 5 (7.1) 80 (20.5) 85 (18.5) 0.008 19 (35.8) 68 (23.8) 87 (25.7) 0.065
Headache 13 (18.6) 83 (21.3) 96 (20.9) 0.607 13 (24.5) 65 (22.7) 78 (23.0) 0.775
Dizziness 1 (1.4) 71(18.2) 72 (15.7) <0.001 9 (17.0) 58 (20.3) 67 (19.8) 0.580
Fatigue 1 (1.4) 29 (7.4) 30 (6.5) 0.061 16 (30.2) 44 (15.4) 60 (17.7) 0.009
Vomiting 10 (14.3) 26 (6.7) 36 (7.8) 0.029 2 (3.8) 33 (11.5) 35 (10.3) 0.088
Blood in urine 1 (1.4) 29 (7.4) 30 (6.5) 0.061 11 (20.8) 16 (5.6) 27 (8.0) <0.001
Fever 1 (1.4) 27 (6.9) 28 (6.1) 0.077 2 (3.8) 21 (7.3) 23 (6.8) 0.343
Itching 2 (2.9) 30 (7.7) 32 (7.0) 0.143 4 (7.5) 13 (4.5) 17 (5.0) 0.358
Diarrhoea 2 (2.9) 18 (4.6) 20 (4.3) 0.507 3 (5.7) 11 (3.8) 14 (4.1) 0.542
Light sensitivity 0 (0.0) 25 (6.4) 25 (5.4) 0.029 0 (0.0) 7 (2.4) 7 (2.1) 0.250
Joint pain 2 (2.9) 15 (3.8) 17 (3.7) 0.686 1 (1.9) 6 (2.1) 7 (2.1) 0.921
Blood in stool 0 (0.0) 4 (1.0) 4 (0.9) 0.395 4 (7.5) 3 (1.0) 7 (2.1) 0.002
Red skin 1 (1.4) 8 (2.1) 9 (2.0) 0.729 1 (1.9) 3 (1.0) 4 (1.2) 0.604
Breathing difficulty 2 (2.9) 11 (2.8) 13 2.8) 0.061 0 (0.0) 3 (1.0) 3 (0.9) 0.454
� chi-square test
a Preschool-aged children
b School-aged children.
https://doi.org/10.1371/journal.pone.0229247.t002
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Conclusions
This study adds evidence that chemotherapy for the control of schistosomiasis and soil-trans-
mitted helminthiasis with PZQ and ALB is safe, although mild to moderate cases of AEs are
expected. In these two surveys of AEs, we recorded 3.1% of children reporting medical atten-
tion due AEs after the medication. To assess the safety of co-administration of PZQ and ALB
with artemeter-lumefantrine for positive cases of uncomplicated malaria in children, more
standardized methodologies are needed to discriminate drug-related AEs from the clinical
manifestations of the infections studied.
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Table 3. Association between AEs and characteristics of participants in two AEs survey moments.
1st survey 2nd survey
Characteristics Total 257/339 (75.8%) Adjusted 0R (95% CI) P value Total 184/339 (54.3%) Adjusted OR (95% CI) P value
Gender
Female 113/146 (77.4) 1 - 75/146 (51.4) 1 -
Male 144/193 (74.6) 0.96 (0.54–1.70) 0.904 109/193 (56.5) 1.18 (0.75–1.84) 0.463
Age group
2–5 y 45/55 (81.8) 1 25/55 (45.5) 1 -
6–8 y 51/65 (78.5) 0.80 (0.30–2.09) 0.652 38/65 (58.5) 1.95 (0.91–4.18) 0.085
9–11 y 84/111 (75.7) 0.66 (0.28–1.59) 0.366 64/111 (57.7) 2.01 (1.00–4.05) 0.049
12–15 y 77/108 (71.3) 0.40 (0.16–0.95) 0.040 57/108 (52.8) 1.69 (0.84–3.39) 0.139
S. haematobium eggs
Negative 97/130 (74.6) 1 - 102/195 (52.3) 1 -
Light (1-49eggs) 17/25 (68.0) 0.63 (0.23–1.71) 0.370 28/46 (60.9) 1.43 (0.73–2.80) 0.291
Moderate (50-499eggs) 75/100 (75.0) 1.13 (0.59–2.19) 0.700 29/62 (46.8) 0.73 (0.40–1.35) 0.324
Heavy (�500eggs) 68/84 (81.0) 2.11 (0.76–3.26) 0.213 25/36 (69.4) 2.72 (1.18–6.24) 0.018
STHs Eggs
Negative 205/251 (81.7) 1 - 159/298 (53.4) 1 -
Positive 52/88 (59.1) 2.11 (0.42–10.57) 0.361 25/41 (61.0) 0.43 (0.08–2.15) 0.310
Hymenolepis nana eggs
Negative 241/313 (77.0) 1 - 177/328 (54.0) 1 -
Positive 16/26 (61.5) 1.77 (0.36–8.51) 0.475 7/11 (63.6) 1.95 (0.41–9.11) 0.395
Plasmodium parasites
Negative 235/307 (76.5) 1 - 179/327 (54.7) 1 -
Positive 22/32 (68.8) 0.82 (0.34–1.94) 0.653 5/12 (41.7) 0.59 (0.17–2.00) 0.402
Number of infections
Null 191/228 (83.8) 1 - 159/298 (53.4) 1 -
One 59/94 (62.8) 0.14 (0.30–0.69) 0.016 21/33 (63.6) 3.02 (0.58–15.69) 0.188
Two 7/17 (41.2) 0.04 (0.01–0.49) 0.011 4/8 (50.0) 1.67 (0.50–5.63) 0.402
Anaemia
No 65/82 (79.3) 1 - 89/159 (56.0) 1 -
Yes 192/257 (74.7) 0.69 (0.36–1.34) 0.282 95/180 (52.8) 0.78 (0.50–1.24) 0.309
CI: confidence interval, OR: odds ratio, SHT: soil-transmitted helminths.
https://doi.org/10.1371/journal.pone.0229247.t003
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